Artal Group Sa Decreased Acceleron Pharma Inc (Call) (NASDAQ:XLRN) Stake By $36.00 Million

August 13, 2018 - By Carol Mulligan

Acceleron Pharma Inc. (NASDAQ:XLRN) LogoInvestors sentiment increased to 1.27 in 2018 Q1. Its up 0.18, from 1.09 in 2017Q4. It increased, as 13 investors sold XLRN shares while 39 reduced holdings. 24 funds opened positions while 42 raised stakes. 38.30 million shares or 0.44% more from 38.14 million shares in 2017Q4 were reported. Jasper Ridge Prns L P holds 12,498 shares. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Moreover, Omega Advisors has 0.07% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). California State Teachers Retirement Sys has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Tiverton Asset Mngmt Ltd Llc holds 0.17% or 61,847 shares in its portfolio. Ameritas Investment Prtn Incorporated has 0.01% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 3,252 shares. Moreover, Geller Advsr Limited Liability Corporation has 0.36% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 18,750 shares. Rhumbline Advisers invested in 36,854 shares. Daiwa Secs Inc accumulated 0% or 250 shares. Waddell & Reed Fincl reported 28,300 shares. Birchview Limited Partnership reported 0.64% stake. Alps Advisors holds 60,670 shares. Eventide Asset Mgmt Ltd Company holds 0.97% in Acceleron Pharma Inc. (NASDAQ:XLRN) or 529,900 shares. Congress Asset Mngmt Ma stated it has 0.01% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Schwab Charles Management holds 0.01% or 192,271 shares.

Since March 6, 2018, it had 0 insider purchases, and 7 sales for $3.31 million activity. $46,232 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Quisel John D on Tuesday, April 3. Rovaldi Christopher sold $134,395 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, April 3. POPS RICHARD F sold $1.55M worth of stock or 37,500 shares. Shares for $46,205 were sold by Kumar Ravindra. 4,600 Acceleron Pharma Inc. (NASDAQ:XLRN) shares with value of $176,772 were sold by Sherman Matthew L.

Artal Group Sa decreased its stake in Acceleron Pharma Inc (Call) (NASDAQ:XLRN) by 88.24% based on its latest 2018Q2 regulatory filing with the SEC. Artal Group Sa sold 750,000 shares as the company’s stock declined 18.55% with the market. The institutional investor held 100,000 shares of the biological products (no diagnostic substances) company at the end of 2018Q2, valued at $4.85 million, down from 850,000 at the end of the previous reported quarter. Artal Group Sa who had been investing in Acceleron Pharma Inc (Call) for a number of months, seems to be less bullish one the $2.19B market cap company. The stock increased 2.22% or $1.03 during the last trading session, reaching $47.5. About 255,178 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 37.77% since August 13, 2017 and is uptrending. It has outperformed by 25.20% the S&P500.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

Among 9 analysts covering Acceleron Pharma (NASDAQ:XLRN), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Acceleron Pharma had 10 analyst reports since February 26, 2018 according to SRatingsIntel. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Neutral” rating given on Friday, June 29 by Goldman Sachs. JP Morgan upgraded the shares of XLRN in report on Monday, February 26 to “Overweight” rating. The rating was downgraded by PiperJaffray to “Neutral” on Tuesday, July 10. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, February 28. The firm has “Buy” rating by Citigroup given on Thursday, March 1. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Friday, July 13 report. The firm earned “Hold” rating on Tuesday, May 22 by Oppenheimer. Barclays Capital maintained it with “Overweight” rating and $54 target in Wednesday, February 28 report. H.C. Wainwright initiated Acceleron Pharma Inc. (NASDAQ:XLRN) on Wednesday, March 28 with “Buy” rating. As per Friday, June 29, the company rating was maintained by Credit Suisse.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The company has market cap of $2.19 billion. The Company’s therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. It currently has negative earnings. The firm is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension.

More notable recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Streetinsider.com which released: “Acceleron Pharma (XLRN) Reports Preliminary Results from Part 1 of ACE-083 Phase 2 Trial in Patients with Charcot …” on July 23, 2018, also Benzinga.com with their article: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs” published on July 28, 2018, Businesswire.com published: “Acceleron Reports Second Quarter 2018 Operating and Financial Results” on August 02, 2018. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) were released by: Fool.com and their article: “Did This Top Biotech Stock Just Go on Sale?” published on July 25, 2018 as well as Benzinga.com‘s news article titled: “Acceleron Pharma Q2 Earnings Preview” with publication date: August 02, 2018.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.